334 related articles for article (PubMed ID: 15769751)
1. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate.
Clair T; Aoki J; Koh E; Bandle RW; Nam SW; Ptaszynska MM; Mills GB; Schiffmann E; Liotta LA; Stracke ML
Cancer Res; 2003 Sep; 63(17):5446-53. PubMed ID: 14500380
[TBL] [Abstract][Full Text] [Related]
5. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.
Ferry G; Tellier E; Try A; Grés S; Naime I; Simon MF; Rodriguez M; Boucher J; Tack I; Gesta S; Chomarat P; Dieu M; Raes M; Galizzi JP; Valet P; Boutin JA; Saulnier-Blache JS
J Biol Chem; 2003 May; 278(20):18162-9. PubMed ID: 12642576
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
[TBL] [Abstract][Full Text] [Related]
7. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Samadi N; Bekele R; Capatos D; Venkatraman G; Sariahmetoglu M; Brindley DN
Biochimie; 2011 Jan; 93(1):61-70. PubMed ID: 20709140
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
[TBL] [Abstract][Full Text] [Related]
9. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site.
Gijsbers R; Aoki J; Arai H; Bollen M
FEBS Lett; 2003 Mar; 538(1-3):60-4. PubMed ID: 12633853
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family.
Sakagami H; Aoki J; Natori Y; Nishikawa K; Kakehi Y; Natori Y; Arai H
J Biol Chem; 2005 Jun; 280(24):23084-93. PubMed ID: 15788404
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin.
Lee HY; Clair T; Mulvaney PT; Woodhouse EC; Aznavoorian S; Liotta LA; Stracke ML
J Biol Chem; 1996 Oct; 271(40):24408-12. PubMed ID: 8798697
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
16. Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2.
Cimpean A; Stefan C; Gijsbers R; Stalmans W; Bollen M
Biochem J; 2004 Jul; 381(Pt 1):71-7. PubMed ID: 15096095
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
19. Regulation and biological activities of the autotaxin-LPA axis.
van Meeteren LA; Moolenaar WH
Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
[TBL] [Abstract][Full Text] [Related]
20. [Function and biological activities of the autotaxin-LPA axis].
Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
